PMID: 18718095Aug 23, 2008Paper

Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab

Zhongguo shi yan xue ye xue za zhi
Wei-Jun GuJian-Yong Li

Abstract

In order to evaluate the efficiency of rituximab combined with fludarabine, cyclophosphamide and rituximab (FCR) regimen for chronic lymphocytic leukemia (CLL). Five patients with CLL were treated with FCR regimen for 2 - 6 courses. FCR regimen included fludarabine 25 mg/m(2) via intravenous drip at day 2 - 4, cyclophosphamide 250 mg/m(2) via intravenous drip at day 2 - 4 and rituximab 375 mg/m(2) via intravenous drip at day 1. Courses were repeated every 4 weeks. Minimal residual disease (MRD) was determined by multiparametic flow cytometry. The results showed that three patients achieved complete remission, 2 patients achieved partial remission. MRD was negative in two patients. In conclusion, FCR is an effective therapeutic regimen for treating CLL patients and is worth to be used in clinic.

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.